Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 30 Neoplasm Metastasis 4 Advanced Breast Cancer 4 Triple Negative Breast Neoplasms 3 Polycystic Ovary Syndrome 3 Neoplasms 3 Endometrial Neoplasms 3 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Infertility 2 Carcinoma, Intraductal, Noninfiltrating 2 Breast Neoplasms, Male 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sexual Dysfunctions, Psychological 1 Recurrence 1 Pathologic Complete Response 1 Neoplasms by Site 1 Leiomyoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 HR+/HER2- Breast Cancer 1 HER2 Negative Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Ductal 1 Breast Neoplasm Female 1 Breast Diseases 1

Interventions

ribociclib 1 Letrozole 1 Goserelin 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2 Negative Breast Cancer × Letrozole × 30 days × Clear all

NCT06953882 2026-05-26

SELECT

Yale University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡